摘要
目的:观察骨化三醇联合贝那普利治疗原发性IgA肾病的临床疗效及安全性。方法:将60例原发性IgA肾病且24小时尿蛋白定量1.0~3.0g的患者随机分为贝那普利组(ACEI组)、骨化三醇联合贝那普利治疗组(VD3+ACEI组)各30例,观察治疗12周,检测治疗前后24小时尿蛋白定量、血清肌酐、尿素氮、血钾及血钙。结果:两组治疗后尿蛋白定量均较治疗前下降,差异有统计学意义(P〈0.01),且VD3+ACEI组较ACEI组下降更明显,差异有统计学意义(P〈0.05)。结论:骨化三醇联合贝那普利治疗可降低原发性IgA肾病患者的尿蛋白,未发现高血钾、高血钙不良反应发生。
Objective:To observe the effectand safety of calcitriol combined with benazepril treatment for primary IgA nephropathy. Methods:Sixty cases with primary IgA nephropathy and 24 hours urine protein quantitative in 1.0 - 3.0g were randomly divided into the benazepril group(ACEI group ),calcitriol combined with benazepril treatment group (VD3 + ACEI group) 30 cases each,to observe treatment for 12 weeks,24 hours urine protein quantitative,serum creatinine, blood urea nitrogen,potassium and calcium were measured before and after the treatment.Results:In two groups after treatment, urine protein quantitative was significantly decreased,the difference was statistically significant(P〈 0.01),and in VD3 + ACEI group was decreased more obviously than in ACEI group,the difference was statistically significant(P 〈 0.05).Conclusion:Calcitriol combined with benazepril treatment can reduce urine protein in patients with primary IgA nephropathy,no high potassium,high blood calcium found adverse reactions occur.